Ostrum Asset Management’s Quest Diagnostics DGX Stock Holding History

Ostrum Asset Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.41M	Sell	17,402 -14,769	-46%	-$2.87M	0.19%	75
2025 Q4	$5.58M	Buy	32,171 +1,536	+5%	+$280K	0.27%	50
2025 Q3	$5.84M	Buy	30,635 +1,890	+7%	+$335K	0.26%	61
2025 Q2	$5.16M	Buy	28,745 +2,589	+10%	+$450K	0.24%	66
2025 Q1	$4.43M	Sell	26,156 -4,950	-16%	-$813K	0.23%	75
2024 Q4	$4.69M	Sell	31,106 -6,898	-18%	-$1.07M	0.41%	47
2024 Q3	$5.9M	Sell	38,004 -8,775	-19%	-$1.31M	0.49%	36
2024 Q2	$6.4M	Sell	46,779 -506	-1%	-$69.3K	0.56%	27
2024 Q1	$6.29M	Buy	47,285 +19,468	+70%	+$2.53M	0.5%	29
2023 Q4	$3.84M	Sell	27,817 -10,162	-27%	-$1.34M	0.33%	79
2023 Q3	$4.63M	Buy	37,979 +4,423	+13%	+$589K	0.43%	50
2023 Q2	$4.72M	Sell	33,556 -207	-0.6%	-$28.5K	0.4%	61
2023 Q1	$4.78M	Buy	+33,763	New	+$4.83M	0.42%	56

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Ostrum Asset Management's DGX Position: Q1 2026 in Review

Ostrum Asset Management reduced its Quest Diagnostics (DGX) stake by 46% in Q1 2026, selling an estimated $2.87M and leaving 17,402 shares worth $3.41M. The position accounts for 0.19% of the portfolio, ranked #75.

Ostrum Asset Management first reported a position in DGX in Q1 2023 and has held it in 13 quarters since. The position peaked at $6.4M in Q2 2024. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Ostrum Asset Management held 17,402 shares of Quest Diagnostics worth $3.41M as of Q1 2026.
Ostrum Asset Management sold 14,769 Quest Diagnostics shares in Q1 2026, an estimated $2.87M.
Quest Diagnostics made up 0.19% of Ostrum Asset Management's portfolio in Q1 2026, its #75 holding.
Ostrum Asset Management first reported a position in Quest Diagnostics in Q1 2023 and has held it in 13 quarters since.
Ostrum Asset Management's Quest Diagnostics position peaked at $6.4M in Q2 2024.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Ostrum Asset Management's 13F filing for Q1 2026, filed 14 May 2026.